Onco Wiki / Enfermedad

Carcinoma paratiroideo

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDDIS-PARATHYROID-CARCINOMA
TipoEnfermedad
Aliaces
Carcinoma paratiroideo asociado a CDC73Carcinoma paratiroideo asociado a la HRTP2Carcinoma paratiroideo asociado a MEN1 (raro)Cáncer de paratiroidesКарцинома прищитоподібної залози
Situaciónreviewed 2026-05-18 | pending_clinical_signoff
EnfermedadesNinguna declarada
FuentesSRC-NCCN-NET-2025 SRC-NCCN-THYROID-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Fuente YAML

icd_o_3_morphology8140/3
icd_o_3_topography["C75.0"]
icd_10C75.0
who_classificationWHO Endocrine and Neuroendocrine Tumours 5th ed (2022): Parathyroid carcinoma — diagnostic criteria require evidence of invasion (capsular / vascular / soft-tissue / lymph node / metastasis) and not just atypical histology

Capacidades

Notas

Diagnosis is histologic-plus-invasive (capsular / vascular / soft- tissue invasion or metastasis) — atypical adenoma alone is not parathyroid carcinoma. Germline CDC73 / HRPT2 testing recommended at diagnosis for any parathyroid carcinoma (HPT-JT cascade). Treatment: en-bloc resection of parathyroid + ipsilateral thyroid lobe + central lymph nodes (R0 is the strongest prognostic factor; do NOT shell out the tumor at index surgery). Recurrent / metastatic disease: re- resection where feasible; calcimimetic (cinacalcet) for hypercalcemia control; bisphosphonates / denosumab for skeletal disease; pembrolizumab in MSI-H / TMB-high subset. No standard cytotoxic regimen with consistent activity.

Utilizado por

Relevancia terapéutica

Algoritmos

Enfermedad

Fármaco

Indicación

Señal de alerta

Esquema terapéutico